

2425 NORTH 55TH STREET  
BOULDER, COLORADO 80301-5700

PHONE: (303) 447-1773  
FAX: (303) 447-1758

## CITREX, INC.

**MTT Cell Viability Assay**  
***HepG2 Human Liver and RKO Human Colon Cells***  
**Test Article: Citrex B**  
**Study Number: CIT-0900b**  
**September, 2000**

### SUMMARY OF RESULTS

The test article, Citrex B, was analyzed for cytotoxicity at Xenometrix in September 2000. Data are shown on the following pages in Figures 1 and 2. The following is summary of the data obtained:

- The LC<sub>50</sub> for Citrex B in HepG2 human liver cells was 0.0026%.
- The LC<sub>50</sub> for Citrex B in RKO human colon cells was 0.001%.

The LC<sub>50</sub> is the concentration of test article estimated to cause 50% mortality in the exposed population. HepG2 cells and RKO cells were grown in separate wells of a 96-well collagen-treated (for better cell adherence) tissue culture plate and exposed to one of several concentrations of Citrex B for 48 hours. Culture viability was measured at each dose by the application of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT). MTT is a hydrogen acceptor, which can be taken up by viable cells and reduced by mitochondria to yield a purple formazan salt. By solubilizing these formazan salt crystals in DMSO, this turnover can be measured spectrophotometrically. Only viable cells can carry out this reaction. LC<sub>50</sub> values represent the concentrations that reduce the MTT value to 50% of the negative control.


Study Director: Elaine Shen, Ph.D.  
Scientist, Client Research and Operations

Signed: Elaine Shen

Date: September 16, 2000


This report applies to the sample, or samples, investigated and is not necessarily indicative of the quality or condition of apparently identical or similar products. As a mutual protection to clients, the public and this Laboratory, this report is submitted and accepted for the exclusive use of the client to whom it is addressed and upon the condition that it is not to be used, in whole or in part, in any advertising or publicity matter without prior written authorization from Xenometrix, Inc.

Figure 1. Effects of Citrex B on Human Liver Cell (HepG2) Viability



% Citrex Liquid	% Viability
0	100
0.0005	92.64
0.002	70.81
0.004	1.16
0.008	1.64
0.016	2.39
0.032	2.94

Figure 2. Effects of Citrex B on Human Colon Cell (RKO) Viability



% Citrex Liquid	% Viability
0	100
0.000125	88.43
0.00025	83.55
0.0005	68.94
0.001	50.22
0.002	18.34
0.004	1.92